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Abstract 
Background: Synaptic dysfunction is a key event in pathogenesis of neurodegenerative diseases such as Alzheimer’s 
disease (AD) where synapse loss pathologically correlates with cognitive decline and dementia. Although evidence 
suggests that aberrant protein production and aggregation are the causative factors in familial subsets of such 
diseases, drugs singularly targeting these hallmark proteins, such as amyloid-β, have failed in late stage clinical trials. 
Therefore, to provide a successful disease-modifying compound and address synaptic dysfunction and memory loss 
in AD and mixed pathology dementia, we repurposed a clinically proven drug, CMZ, with neuroprotective and anti-
inflammatory properties via addition of nitric oxide (NO) and cGMP signaling property.
Results: The novel compound, NMZ, was shown to retain the GABAA potentiating actions of CMZ in vitro and seda-
tive activity in vivo. Importantly, NMZ restored LTP in hippocampal slices from AD transgenic mice, whereas CMZ was 
without effect. NMZ reversed amnestic blockade of acetylcholine receptors by scopolamine as well as NMDA receptor 
blockade by a benzodiazepine and a NO synthase inhibitor in the step-through passive avoidance (STPA) test of learn-
ing and working memory. A PK/PD relationship was developed based on STPA analysis coupled with pharmacokinetic 
measures of drug levels in the brain: at 1 nM concentration in brain and plasma, NMZ was able to restore memory 
consolidation in mice.
Conclusion: Our findings show that NMZ embodies a promising pharmacological approach targeting synaptic 
dysfunction and opens new avenues for neuroprotective intervention strategies in mixed pathology AD, neurodegen-
eration, and dementia.
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Background
Of age-related dementia, the most common form, Alz-
heimer disease (AD) a devastating neurodegenerative 
disorder, presents a severe economic and social burden 
worldwide [1]. In the rare, familial form of AD (~1 % of 
cases) [2], genetic mutations in specific proteins, APP, 
PS1, and PS2, cause insoluble amyloid-β peptide (Aβ) 
aggregation and elevated levels of neurotoxic, soluble 
Aβ1–42 [3–5]. In sporadic, late-onset AD, the appear-
ance of Aβ neuropathology has supported the theory of 
Aβ deposition as the primary causative factor leading to 
neuronal death [6]. This hypothesis has resulted in the 
dominance in AD in drug discovery of transgenic mouse 
models that overexpress the mutant human genes linked 
to familial AD; however, to date, all therapeutics directly 
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targeting Aβ production, aggregation, or clearance have 
failed primary endpoints in Phase 3 clinical trials [7–11].
Approximatively, half of the patients diagnosed with 
dementia, have additional pathologies associated to the 
hallmarks of Aβ and tau, including vascular dementia, 
and dementia with Lewy bodies [12, 13]. It is also increas-
ingly recognized that AD and dementia are multifactorial 
diseases, with contributions to onset and progression 
including early synaptic failure [14], inflammation [15], 
oxidative stress [16], mitochondrial dysfunction [17], 
cerebrovascular impairment [18, 19], depletion of neu-
rotrophins [20, 21], and excitotoxicity [22]. It is argued 
that effective treatment should target two or more factors 
in disease pathogenesis [23]. In this context, drug repo-
sitioning is also an attractive approach [24]. The clinical 
agent, chlomethiazole (CMZ), is neuroprotective in ani-
mal models [25], with reported amelioration of inflam-
mation, mitochondrial dysfunction, and excitotoxicity 
[26–28]. Therefore, CMZ was proposed as a candidate 
for combination therapies treating neuronal injury [29, 
30]. In line with this postulate, we have reported that 
CMZ is neuroprotective in primary neurons treated with 
neurotoxic, oligomeric Aβ1–42 (oAβ) [31].
Based on the strong a rationale for targeting synap-
tic dysfunction in AD [32], we sought to modify CMZ 
to incorporate this activity without loss of other attrib-
utes. Phosphorylation of cAMP-response element bind-
ing protein (CREB) is necessary for memory formation 
and synaptic strengthening and the work of Kandel has 
highlighted a role for nitric oxide induced release of 
cyclic guanosine 3,5-monophosphate (cGMP) in CREB 
activation in the hippocampus [33–35]. More recently 
decreased activity of pCREB has been demonstrated in 
homogenates taken from post-mortem AD patients [36]. 
Moreover, dysfunctional CREB signaling has been placed 
at the center of AD-related gene networks [37]. Accord-
ingly, an analogue of CMZ, 4-methyl-5-(2-(nitrooxy) 
ethyl) thiazol-3-ium chloride (NMZ), was engineered 
to activate NO/cGMP/CREB signaling and to retain the 
beneficial activity of CMZ.
CMZ possesses anticonvulsant, anxiolytic, and sedative 
properties that derive, at least in part, from potentiation 
of GABA signaling, which has been confirmed by direct 
study of the actions of CMZ on GABA receptors [38, 
39]. We successfully confirmed the retention of NMZ of 
these proprieties precisely, via potentiation of the α1β2γ2 
GABAA receptor and through study of sedative actions 
in vivo. Restoration of LTP was designed into the struc-
ture of NMZ and therefore comparison of NMZ and 
CMZ in hippocampal slices from the transgenic APP/
PS1 mouse was used to confirm that the design of NMZ 
did add function over CMZ. Several agents have been 
reliably used to induce amnesia in wild type mice, which 
can be tested using the step-through passive avoidance 
(STPA) task. NO/cGMP signaling regulates the strength 
of synaptic transmission in an activity-dependent man-
ner in the hippocampus and functions in both pre- and 
postsynaptic neurons [35, 40], therefore NMZ was tested 
using agents that induce amnesia by blockade of cholin-
ergic, glutamatergic, and nitrergic signaling. Correlation 
of pharmacokinetic measurements of brain and plasma 
concentrations of NMZ with pharmacodynamic analysis 
of cognitive function in the face of scopolamine-induced 
amnesia were used to define PK/PD relationships.
Re-engineering of a neuroprotective agent that 
addresses multiple mechanisms contributing to neuro-
degeneration to provide a brain bioavailable small mol-
ecule that restores LTP and memory is a novel approach 
towards treatment of age-related and mixed pathology 
dementia, including the most common form, AD.
Results
NMZ is a GABAA potentiator and shows a sedative effect 
at higher doses than CMZ
The core anticonvulsant, sedative, and anxiolytic proper-
ties of CMZ derive, at least in part, from GABA poten-
tiation. Measurements using the Xenopus oocyte model 
expressing α1β2γ2 GABAA receptors confirmed that 
NMZ retained GABAA potentiating activity in  vitro 
(Fig.  1a). As a measure of sedation, motor impairment 
was assessed using latency to fall on a rotating rod for 
C57BL/6 mice (Fig. 1b). Preliminary experiments showed 
a significant effect of CMZ (50 mg/kg i.p.), therefore, this 
and an equimolar dose of NMZ were selected. All ani-
mals were trained in the task for 3–5 days prior to experi-
ment, until latency to fall reached 100 ± 10 s. At 10 min 
post injection, CMZ and NMZ groups had a latency to 
fall of 14.2 ± 9.8 and 38.7 ± 5.4 s respectively (p < 0.001), 
showing motor impairment over vehicle treated ani-
mals (108.1  ±  6.2  s). At 30  min, only CMZ showed a 
significant deficit (35.0 ± 12.8 s; p < 0.001), versus vehi-
cle (115.8  ±  6.3  s; NMZ 93.5  ±  5.4  s), and at 60  min, 
CMZ retained significant sedative actions (73.0 ± 6.5  s; 
p  <  0.05; vehicle 122.1  ±  10.7  s; NMZ 109.1  ±  7.0  s). 
To test more profound sedation, loss of righting reflex 
(LORR) was assessed in male C57BL/6 mice (Fig.  1c). 
The duration of LORR, defined as failure to place four 
paws on the ground within 30 s after placing the mouse 
on its back, was measured every 2 min for 2 h post drug 
administration. All animals recovered fully after treat-
ment. CMZ significantly induced LORR at doses lower 
than NMZ. At the 125 mg/kg dose, NMZ induced LORR 
for 4.8  ±  1.7  min, which was not statistically signifi-
cant; whereas CMZ at a molar equivalent dose induced 
a significant LORR (23.8 ± 2.7 min). Only at the highest 
dose (175 mg/kg) did LORR reach significance for NMZ 
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(LORR = 90.5 ± 20.9 min, compared to a molar equiva-
lent dose of CMZ: LORR = 66.2 ± 7.7). It is important to 
note that the dose of NMZ needed to induce a transient 
sedative effect, reflected by LORR, was almost 200-fold 
higher than the procognitive dose reported below.
NMZ reverses memory deficits in WT animals 
by consolidating memory
NMZ was designed to add procognitive activity to 
the neuroprotective actions of CMZ, therefore, NMZ 
(1  mg/kg) was tested in male C57BL/6 mice using the 
step-through passive avoidance (STPA) behavioral task, 
in which mice learn to associate a mild electric shock 
(0.5  mA) with the dark side of a light–dark box and 
latency to enter is assessed 24 and 48  h after training. 
A variety of amnestic agents, administered i.p. 30  min 
before training, have been shown to cause loss of memory 
without hindering the ability of animals to learn the task. 
The muscarinic receptor antagonist scopolamine (1 mg/
kg) [41], the NMDA receptor antagonist MK-801 (0.1 mg/
kg), the benzodiazepine diazepam (0.5  mg/kg) [42], 
and the nitric oxide synthase (NOS) inhibitor L-NAME 
(50 mg/kg), were able significantly to inhibit memory as 
reflected by decreased latency in STPA (Fig. 2a). Vehicle 
treated animals reliably show a latency in testing at or 
close to the cutoff threshold of 300 s, which was reduced 
after treatment with amnestic agents. Administration 
of NMZ (1 mg/kg i.p.) 20 min prior to training restored 
memory as shown by significantly increased latency 
(scopolamine 98.1  ±  16.6 vs. 240.7  ±  25.3  s treated; 
MK-801 94.6  ±  9.3 vs. 255.1  ±  15.4  s treated; diaz-
epam 166.7 ±  16.6 vs. 250.9 ±  22.5  s treated; L-NAME 
22.0  ±  10.4 vs. 211.7  ±  31.4  s treated 50  min prior to 
training). To test the effects of oral drug delivery, animals 
were treated with NMZ (20 mg/kg) in drinking water for 
24 h prior to training, again resulting in reversal of a sco-
polamine-induced deficit, tested at 24 h (231.5 ± 19.3 s), 
or 48 h post training (Fig. 2b).
In the STPA task, animals are tested at least 24 h after 
drug administration, therefore, confounding locomotor 
drug effects are highly improbable. The task is also suited 
to correlate pharmacokinetics with pharmacodynamics 
(PK/PD). Using scopolamine-induced amnesia, the time 
of administration of NMZ (1 mg/kg i.p.) was varied from 
120 min prior to 90 min post training (Fig. 2c). NMZ was 
procognitive when administered within 40  min prior to 
the start of training, while not effective when given ear-
lier (−120 min: 134.0 ± 11.3 s; −60 min: 125.2 ± 37.1 s; 
−40 min: 263.0 ± 17.1 s; −20 min: 280.0 ± 11.4 s). When 
administered after training, the procognitive effect was 












































































Fig. 1 Retention of GABAA potentiating, and attenuated sedative 
activity in NMZ relative to CMZ. a Oocytes expressing the α1β2γ2 
GABAA receptor (n = 6) showed a dose response to increasing 
concentrations of NMZ in the presence of GABA (6 µM). Addition of 
picrotoxin (200 µM) caused 96 ± 2 % inhibition of the potentiated 
GABA response (n = 4) (O). Data show mean ± SD normalized to the 
saturated 200 µM GABA response. b Male C57Bl/6 mice (n = 5–16) 
were injected i.p. with CMZ (45 mg/kg) or an equimolar dose of NMZ 
before testing for their latency to fall on a rotating rod (RR). NMZ 
showed less sedation than CMZ at various time points. Data show 
mean ± SEM. Statistical significance relative to vehicle is indicated 
by *p < 0.05, **p < 0.01, ***p < 0.001, using one-way ANOVA with 
Dunnett’s post hoc test. c Male C57BL/6 mice (n = 4–5) were injected 
with escalating doses of CMZ and NMZ and loss of righting reflex 
(LORR) was measured over 2 h. NMZ showed less sedation than CMZ, 
and no LORR was observed for NMZ until 125 mg/kg. Data show 
mean ± SEM. Non-zero statistical significance by one-sample t test is 
indicated by *p < 0.05, ***p < 0.001
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significant at least up to 90 min (+30 min: 243.0 ± 34.0 s; 
+60 min: 300.0 ± 0.0 s; +90 min: 228.1 ± 71.9 s). Task 
acquisition during training did not differ significantly 
between vehicle and NMZ treated animals (data not 
shown).
NMZ is orally bioavailable in the brain
The loss of procognitive activity when NMZ is admin-
istered >60  min before training is indicative of drug 
clearance and a T1/2 < 60 min in mice. The plasma and 
brain concentrations of NMZ and its denitrated metabo-
lite, 5-(2-hydroxyethyl)-4-methylthiazole (HMZ), were 
measured by LC–MS/MS (Fig.  3a), since HMZ is itself 
known to have bioactivity in  vivo [43]. At early time 
points after bolus injections of NMZ at sedating (50 mg/
kg i.p.) or procognitive doses (1 mg/kg i.p.), NMZ brain 
concentrations of 10.7  μM and 81.3  nM were meas-
ured, respectively. In STPA, NMZ is procognitive when 
administered 20 min prior to training, but loses activity 
administered 60 min prior to training: corresponding to 
brain levels of NMZ of 10.2 and 1.01  nM respectively. 
However, we also observed that NMZ administration 
prior to training is not required to restore memory, but 
that NMZ functions by consolidating memory when 
administered after training. The brain concentrations of 
NMZ and HMZ 5  h after injection were only 0.32 and 
5.7 nM, respectively. In place of drug delivery in drink-
ing water, drug was delivered in hydrogel that mice read-
ily consume for hydration when drinking water is made 
unavailable. This delivery method achieves a relatively 
constant drug concentration throughout the awake-
period, simulating an extended release clinical formula-
tion [44]. Oral administration of NMZ (20 mg/kg) over 
24 h, representing a procognitive dose in STPA, resulted 
in brain concentrations of NMZ and HMZ of 0.73 and 
3.41  nM, respectively. Under these conditions, brain 
and plasma concentrations were not significantly differ-
ent. Taken together, these measurements indicate that 
the brain concentration of NMZ required for memory 
consolidation after amnestic insult is approximately 
0.5–1.0 nM. The measured concentration of HMZ could 
be used as a surrogate for the maximum theoretical con-




































































































































































































Fig. 2 Reversal of induced amnestic deficits by multiple agents in 
STPA. a Male C57BL/6 mice (n = 5–10) treated with vehicle or NMZ 
(1 mg/kg, single dose i.p.; or 20 mg/kg/day, oral drinking water) after 
being administered with diverse amnestic agents were tested for 
their latency to enter the dark side of the STPA apparatus at 24 h after 
training. NMZ reversed memory deficits induced by scopolamine 
(1 mg/kg), MK-801 (0.1 mg/kg), diazepam (0.5 mg/kg), and L-NAME 
(50 mg/kg). b Male C57BL/6 mice with scopolamine-induced deficits 
treated with NMZ showed reversal of latency to enter the dark side of 
the chamber 24 and 48 h after training. Statistical significance is indi-
cated by ***p < 0.001 compared with the respective saline control for 
each time point, using unpaired t test. c In scopolamine induced defi-
cits, NMZ demonstrated reversal of cognitive deficits when admin-
istered i.p. between 40 min prior to training (−40 min) and 90 min 
after training (+90 min); but no significant effect was observed when 
administered 60 or 120 prior to training. Data show mean ± SEM. Sta-
tistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 
compared with the respective saline control for each treatment, using 
one-way ANOVA with Dunnett’s post hoc test
◂
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NMZ, but not CMZ, restores LTP in hippocampal slices 
from APP/PS1 mice
In hippocampal slices from 3-month-old male mice, the 
effect of NMZ and CMZ on long-term potentiation (LTP) 
was measured in the CA3-CA1 pathway. After 15  min 
of baseline collection, drug (100 μM) was added to the 
bath solution for 5 min prior to induction of LTP using 
three trains of ten theta bursts, and the resulting fEPSP 
were recorded in the CA1 area for 120  min. CMZ had 
no significant effect, whereas NMZ induced a significant 
increase in fEPSP slope after LTP induction compared to 
the untreated transgenic, to levels indistinguishable from 
WT control (Fig. 4). NMZ perfusion of WT hippocam-
pal slices had no significant effect (data not shown). It is 
important to note that NMZ treatment had no effect on 
LTP induced in hippocampal slices from WT mice, but 
restored LTP in slices from APP/PS1 mice. This obser-
vation is compatible with the ability of NMZ to activate 
NO/cGMP/pCREB signaling, when signaling is impaired.
Discussion
The Amyloid Hypothesis, derived from convergence of 
genetic, cell biological, and pathological studies [45, 46], 
states that a primary effect of genetic alterations that 
cause familial AD is alteration of Aβ production or clear-
ance in a way that promotes its aggregation and accumu-
lation in the brain. However, it remains unclear precisely 
what role Aβ plays in disease pathogenesis, since Aβ 
accumulation does not correlate well with the extent of 
neuronal loss or cognitive dysfunction [47]. Lowering 
brain Aβ levels has remained the primary target for ther-
apeutic intervention in AD; however, the failure of mul-
tiple such therapeutic agents to reach primary endpoints 
in phase 3 clinical trials [48, 49], emphasizes the urgent 
need for new approaches. In a substantial population of 
dementia patients with AD pathology, the correlation of 
Aβ histopathology with cognitive decline is poor [12, 13], 
and Aβ-specific therapeutics would be expected to fail in 
this clinical population. Other aging-associated diseases, 
such as vascular lesions and diabetes, are also linked to 
AD pathogenesis [50, 51]. In addition, AD is a multifac-
torial disease, many contributors to which are common 
to other dementias and comorbid diseases, for example, 
glutamate excitotoxicity, oxidative stress, and inflamma-
tion [52]. Neuroprotective agents have been targeted at 
these and other contributors to neuronal loss and we rea-
soned that one of these, CMZ, would provide a starting 
point for modest redesign. An anticonvulsant and anxi-
olytic, CMZ was repurposed in Phase 3 clinical trials as 
a neuroprotective drug for use in spinal cord injury and 
ischemic stroke [29, 53, 54], and is prescribed for anxiety 
and agitation in the elderly [55].
In this context, our redesigned molecule, NMZ, was 












































Fig. 3 Pharmacokinetics study on male C57BL/6 mice treated with NMZ, single dose (50 or 1 mg/kg, i.p.) or supplied in hydrogel (20 mg/kg/day), 
showing bioavailability in brain and plasma at various time points after initiation of treatment. The estimated t½ for i.p. administration is 10 min
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of CMZ, a positive allosteric modulator of GABAA func-
tion, which potentiates the function of the inhibitory 
neurotransmitter GABA in the brain [56, 57] and there-
fore attenuates the glutamate-induced excitotoxic cas-
cade leading to mitochondrial damage and neuronal loss 
[26–28]. CMZ potentiates GABA and muscimol agonism 
at the GABAA receptor without evidence for modulation 
of levels of GABA itself; opens neuronal Ca-dependent 
Cl¯ channels enhancing inhibitory neurotransmission; is 
a direct GABAA receptor agonist at concentrations 100-
fold than those required to potentiate GABA function 
(30 μM); is not a ligand for the GABAB nor benzodiaz-
epine receptors and; potentiates the actions of glycine on 
inhibitory neurotransmission [38, 39]. NMZ was shown 
to potentiate the actions of GABA at the α1β2γ2 GABAA 
receptor without having direct actions on ion current 
gated by this receptor. Loss and recovery of righting 
reflex provides a measure of profound, reversible seda-
tion; whereas latency to fall from the accelerating rotarod 
provides a measure of transient sedation. These tests 
clearly demonstrated that CMZ and NMZ both cause 
transient sedation, but that CMZ is significantly more 
potent. The sedative actions of NMZ further support the 
conclusion that NMZ retains the activity of CMZ at the 
GABAA receptor. Sedation itself is not directly relevant to 
the proposed beneficial actions of NMZ in dementia and 
was observed at a dose 200-fold higher than that required 
to counter memory loss.
Selective pharmacological activation of GABAA recep-
tors has been shown to provide neuroprotection against 
Aβ mediated toxicity [58–60], and the GABA-potentiat-
ing [60, 61] and anti-TNF-α [62, 63] properties of CMZ 
are of clinical utility in AD; nevertheless, we hypoth-
esized that it was essential also to address synaptic dys-
function [64, 65]. Several studies indicate that restoration 
of synaptic failure can be achieved through CREB acti-
vation [66, 67]. The coupling of CREB activation to NO/
cGMP signaling in the hippocampus [34, 68, 69], inspired 
the design of NMZ [70, 71]. We and others have demon-
strated that agents activating NO/cGMP/CREB can sig-
nificantly improve LTP and cognitive function in mice 
and rats [72, 73], including in studies of scopolamine-
induced amnesia [74, 75]. NMZ treatment was able to 
reverse deficits in working memory in the STPA task 
induced by blockade of muscarinic and NMDA recep-
tors, in addition to deficits induced by diazepam and 
inhibition of nitric oxide synthase (NOS). More impor-
tantly, by varying the time of drug administration, we 
demonstrated that NMZ reverses cholinergic deficits 
administered 90 min after training, functioning via mem-
ory consolidation. The cholinergic hypothesis remains 
relevant to age-related dementia and AD [76, 77].
PK/PD relationships were also obtained for NMZ 
actions on working memory by varying the time of drug 
administration. Administration of NMZ i.p. at 1  mg/
kg and p.o. at 20 mg/kg/day gave approximate peak and 
trough brain concentrations of 80 and 0.5  nM, respec-
tively. The loss of procognitive activity corresponded to 
brain concentrations of NMZ falling below 1  nM dur-
ing training. Oral delivery of NMZ at 20 mg/kg/day was 
procognitive and yielded a mean brain concentration of 
0.73  nM. The measured brain/plasma ratio approached 
unity and the observed sedative activity required con-
centrations of NMZ in brain tissues reaching 10 µM. The 
high potency of NMZ, in  vivo, for cognition enhance-
ment (~1  nM) and the large separation of sedative and 
procognitive actions (~105-fold) is encouraging for clini-
cal efficacy and safety. In accord with predictions for 
improvement of the function of CMZ by incorporat-
ing NO/cGMP/CREB signaling in NMZ, perfusion of 
Fig. 4 Beneficial effects seen in LTP from NMZ treatment in APP/
PS1 mice. a, b LTP was measured in the CA1 region of hippocampal 
sections in 4 month old male APP/PS1 mice or littermate controls 
(n = 5–8) treated with CMZ (a) or NMZ (b). NMZ showed restora-
tion of LTP in APP/PS1 mice to WT levels, whereas the effects of 
CMZ were not significant. Statistical significance was analyzed by 
two-way ANOVA with repeated measures: WT veh (n = 6) vs. WT 
NMZ (n = 6): F(1,10) = 1.106 p > 0.05 No Sig.; WT veh vs. APP/PS1 
veh: F(1,12) = 18.86 p < 0.05 Sig; APP/PS1 veh (n = 8) vs. APP/PS1 
NMZ (n = 7): F(1,13) = 17.71 p < 0.05 Sig; WT NMZ vs. APP/PS1 NMZ: 
F(1,11) = 0.02351 p > 0.05 No Sig
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hippocampal slices from transgenic APP/PS1 mouse with 
NMZ, but not CMZ, rescued LTP in this model of AD.
Conclusions
In summary, NMZ, an orally active, brain-bioavailable 
small molecule represents a novel therapeutic approach 
to dementia and AD. The re-engineering of a clinical neu-
roprotective agent, CMZ, to address synaptic dysfunc-
tion by incorporating the capacity to activate NO/cGMP/
CREB signaling was achieved without loss of the GABAA 
potentiating actions of the parent drug. The increasing 
recognition that AD and age-related dementia may have 
underlying mixed pathology, supports a small molecule 




The synthesis of NMZ followed standard acidic nitra-
tion procedures from 4-methyl-5-(2-hydroxyethyl)-
1,3-thiazole, followed by salt formation with HCl and 
crystallization. Purity as assessed by chromatography and 
spectroscopy was greater than 98 %. NMZ is a crystalline 
white solid: mp 107–108 °C (d) [72].
Animals
All animal care and procedures were conducted with 
approved institutional animal care protocols and in 
accordance with the NIH Guide for the Care and use of 
Laboratory Animals. All animal protocols were approved 
by the University of Illinois at Chicago Institutional Ani-
mal Care and Use Committee and cognate committees 
at Columbia University. Double transgenic mice (APP/
PS1) expressing both the human APP695K670N/M671L and 
PS1M146L mutations were compared with wild type lit-
termates and housed at Columbia University [78]. Male 
C57BL/6 mice were obtained from Charles River Labora-
tories (Wilminton, MA, USA) and used for bioavailability 
studies (3 months of age), and STPA and sedation stud-
ies (5–8  months of age), and housed at UIC. Food and 
water were available ad libitum, except during the vehicle 
and drug treatment periods using either drinking water 
or hydrogel. Hydrogel preparation was as previously 
described [44]. Stability of NMZ in hydrogel or drinking 
water was assayed, showing no significant reduction of 
drug concentration. For electrophysiology experiments, 
Xenopus laevis toads, were used as the source of oocytes 
for engineered expression of α2β2γ2 GABAA receptors, 
were obtained from Xenopus One (Ann Arbor, MI, USA). 
All animal maintenance and surgical procedures on X. 
laevis conformed to UIC institutional policies (BRL pro-
tocol 13-125) and to the Statement for the Use of Animals 
in Ophthalmic and Vision Research adopted by the Asso-
ciation for Research in Vision and Ophthalmology.
Electrophysiology
GABAA potentiation Experiments were conducted on 
Xenopus laevis oocytes expressing α1β2γ2 GABAA (rat 
α1, rat β2 and human γ2S) receptors using methods pre-
viously described [31]. Briefly, oocytes were prepared by 
cRNA injection and studied by two-electrode voltage-
clamp recording. Oocytes were superfused with Ringer 
solution at a rate of ~1  ml  min−1. Glass micropipettes 
for oocyte recording were prepared with a resistance of 
1–10 MΩ when filled with 3 M KCl. Test solutions were 
delivered via multiple channels from separate reservoirs 
by a gravity flow system. Membrane current data were 
obtained using Clampex 8.2 and analyzed using Clamp-
fit 10.0 (Axon Instruments) and OriginPro7.5 (OriginLab 
Corporation, Northampton, MA). LTP Mice were sacri-
ficed by cervical dislocation followed by decapitation and 
immediate preparation of 400  μm hippocampal slices. 
Slices were maintained at the interface between a con-
tinuous perfusion of artificial erebrospinal fluid (aCSF) 
and an atmosphere of 95 % O2 and 5 % CO2. After at least 
1  h of recovery, stimulation electrodes were placed in 
stratum radiatum of field CA1 to activate Schaffer/com-
missural fibers and glass recording micripipettes were 
placed in the same layer to record field excitatory post-
synaptic potentials (fEPSPs) in the synaptic zone. Stim-
ulus intensity was set to evoke submaximal fEPSP and 
continuously monitored at 20–60 s intervals for at least 
15  min to establish a stable baseline. As described pre-
viously [79], LTP was induced by theta-burst stimulation 
(TBS), consisting of four-pulse bursts of high frequency 
(100  Hz) stimulation, repeated ten times at 5  Hz. APP/
PS1 hippocampal slices were perfused with test com-
pound (100  μM) for 20  min before inducing LTP. The 
results were expressed as mean ± SEM
Behavior
Evaluation of sedation by rotarod Sedation was meas-
ured using the accelerating rotarod test as previously 
described [31, 80]. Briefly, animals were placed, up to 
four at a time, on individual rods within a lane. Latency 
to fall was detected with a 0.1  s temporal resolution by 
a series of photocells located above the rotating rod in 
the apparatus. Mice were trained for 3–5  days on the 
rotarod prior to testing until the mean latency to fall 
reached 100 ± 10 s. Each training session started with a 
30  s trial on a non-rotating rod, followed by 60  s rotat-
ing at constant speed (4  rpm). Animals were then sub-
jected to open ended time trials on the accelerating rod 
(4–40  rpm within 120  s), and the latency to fall off the 
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rotorod was recorded. Each animal was given four tri-
als per day to obtain a baseline level of performance. 
After drug administration, mean latencies to fall off were 
recorded at different time points (10, 30, and 60 min post 
injection). Loss of righting reflex In LORR test, after drug 
administration, animals are placed on their back on a 
flat tissue paper laid surface maintained at around 30 ℃. 
The time to loss of the righting reflex is recorded. Loss is 
considered to have occurred if the animal remains on its 
back for more than 30 s. Righting reflex is considered to 
be regained when the mice were able to successfully right 
themselves with all four paws touching the floor, twice 
within 20  s [81]. Step through passive avoidance (STPA) 
STPA has been widely used to test long-term work-
ing memory and was performed as we have previously 
described [82–85]. Each animal was given two ip injec-
tions: (1) Amnesic agent (scopolamine 1 mg/kg, MK-801 
0.1 mg/kg, diazepam 0.5 mg/kg, L-NAME 50 mg/kg) or 
saline were given 30 min prior to training plus NMZ or 
saline in the time and delivery method as indicated in 
Fig. 2a. Briefly, mice were habituated in a light/dark box 
prior to training in the same box, in which mice placed 
in the light compartment received an electric shock on 
entering the dark compartment (0.5 mA, 60 Hz for 2 s). 
This training was repeated until latency to enter the dark 
side reached 300  s. At 24  h and/or 48  h post-training, 
animals were individually placed in the light compart-
ment and the latency to enter the dark compartment was 
recorded with a 300 s cutoff.
Brain bioavailability
Three-month-old male C57BL/6 mice were administered 
NMZ by i.p. injection plus hydrogel (1 mg/kg i.p., 20 mg/
kg/day oral) or i.p. injection (50 mg/kg). At the appropri-
ate time point, mice were sacrificed using CO2 asphyxi-
ation. Blood was immediately collected from the dorsal 
aorta in 1  mL K3EDTA tubes (Greiner Vacuette) and 
kept on ice. After centrifugation at (3200×g for 20 min at 
4  °C), the plasma supernatant was collected and imme-
diately processed for analyses. Remaining plasma was 
stored at 80  °C. Following blood collection, each mouse 
was intracardially perfused with ice-cold PBS buffer 
(pH 7.4) and was decapitated. Brain was separated by 
hemisphere and half hemisphere was immediately pro-
cessed for analyses while the other half was flash frozen 
with liquid nitrogen to be stored at −80  °C. Briefly, the 
reconstituted brain and plasma samples were analyzed 
after addition of the internal standard. Each sample was 
analyzed in triplicate and each sample set was analyzed 
with a set of calibration standards. Peak areas for analytes 
and standards were calculated and the amount of each 
compound in each sample was determined using the 
calibration curves (Additional file 1). We have previously 
measured plasma pharmacokinetics of NMZ in rats, 
reporting: AUC-determined oral bioavailability of 20.5 
and elimination half-lives of 32.6 min (p.o.) and 19.0 min 
(i.p.) [72].
Statistics
The data were reported as the mean ± SEM or SD using 
student’s t test and/or one-way ANOVA analysis with 
Tukey’s multiple comparison test, or ANOVA with 
repeated measures, by using Graph-Pad Prism version 
4.00 for Windows, GraphPad Software.
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